Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 3121402, 7 pages
http://dx.doi.org/10.1155/2016/3121402
Research Article

Efficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia

1Department of Clinical Hematology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province 430071, China
2Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi Province 710004, China
3Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province 430071, China

Received 3 July 2016; Revised 13 August 2016; Accepted 17 August 2016

Academic Editor: Michael Silbermann

Copyright © 2016 Honglei Tu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We assessed the clinical effectiveness and safety of CKI (compound Kushen injection) plus standard induction chemotherapy for treating adult acute leukemia (AL). We randomly assigned 332 patients with newly diagnosed AL to control (n = 165, receiving DA (daunorubicin and cytarabine) or hyper-CVAD (fractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone)) or treatment (n = 167, receiving CKI and DA or hyper-CVAD) groups. Posttreatment, treatment group CD3+, CD4+, CD4+/CD8+, natural killer (NK) cell, and immunoglobulin (IgG, IgA, and IgM) levels were significantly higher than those of the control group ( < 0.05), and CD8+ levels were lower in the treatment group than in the control group ( < 0.05). Treatment group interleukin- (IL-) 4 and IL-10 levels were significantly higher compared to the control posttreatment (both p < 0.05) as were complete remission, overall response, and quality of life (QoL) improvement rates (p < 0.05). The control group had more incidences of grade 3/4 hematologic and nonhematologic toxicity (p < 0.05). Responses to induction chemotherapy, QoL improvement, and adverse events incidence between control group patients with acute myeloid leukemia and acute lymphocytic leukemia were not significantly different. CKI plus standard induction chemotherapy is effective and safe for treating AL, possibly by increasing immunologic function.